Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-23

FDA Approved: ABILIFY MAINTENA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ABILIFY MAINTENA (aripiprazole) submitted by Otsuka America Pharmaceutical, Inc., for the long-acting injectable ant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABILIFY MAINTENA (ARIPIPRAZOLE)

Snippet

SUPPL AP for ABILIFY MAINTENA (ARIPIPRAZOLE)